Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease?

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nephron Clinical Practice

• Publication date

  2011-02-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000323739PMID 21325870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

  2010cited by this paper
• Metformin in renal failure--weigh the evidence.

  2009influential reference
• The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

  2009cited by this paper
• Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia

  2008cited by this paper
• Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

  2007cited by this paper
• Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

  2007influential reference
• Metformin and lactic acidosis: cause or coincidence? A review of case reports

  2004cited by this paper
• Lactic acidosis in metformin therapy: searching for a link with metformin in reports of ‘metformin‐associated lactic acidosis’

  2001cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Kidney Function and Age Are Both Predictors of Pharmacokinetics of Metformin

  1995cited by this paper

• Safety of Contrast Agents Administration in Patients with Type 2 Diabetes Mellitus During Metformin Intake

  2024cites this paper
• A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease.

  2023cites this paper
• Diabetische Nierenerkrankung (Update 2023)

  2023cites this paper
• Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension

  2023cites this paper
• Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease

  2022cites this paper
• Carbohydrate metabolism in chronic renal disease

  2022cites this paper
• Prevention of Hyperglycemia

  2021cites this paper
• Citrus fruit-derived flavonoid naringenin and the expression of hepatic organic cation transporter 1 protein in diabetic rats treated with metformin.

  2020cites this paper
• Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease—A Systematic Review and Meta-Analysis

  2020cites this paper
• Toxicity of Metformin and Hypoglycemic Therapies.

  2020cites this paper
• Diabetische Nierenerkrankung (Update 2019)

  2019cites this paper
• Administration of metformin in type 2 diabetes mellitus patients with chronic kidney disease; facts and myths

  2019cites this paper
• Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease.

  2019cites this paper
• A rare combination of severe lactic acidosis and acute pancreatitis due to metformin intoxication: A case report

  2019influential citation
• Integration of immunogenic activation and immunosuppressive reversion using mitochondrial-respiration-inhibited platelet-mimicking nanoparticles.

  2019cites this paper
• Acute renal metabolic effect of metformin assessed with hyperpolarised MRI in rats

  2018cites this paper
• Platelet-mimicking nanoparticles co-loaded with W18O49 and metformin alleviate tumor hypoxia for enhanced photodynamic therapy and photothermal therapy.

  2018cites this paper
• Evaluation of Oral Antidiabetic Dosing and Drug Interactions in Type 2 Diabetic Patients

  2018cites this paper
• Managing hyperglycaemia in patients with diabetes and diabetic nephropathy–chronic kidney disease Summary of recommendations 2018

  2018cites this paper
• Epidemiology and multimorbidity of type 2 diabetes and the risk of major cardiovascular events

  2017cites this paper
• The Phantom of Metformin-Induced Lactic Acidosis in End-Stage Renal Disease Patients: Time to Reconsider with Peritoneal Dialysis Treatment

  2017cites this paper
• Metformin prescribing in low-income and insured patients with prediabetes.

  2017cites this paper
• Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients

  2017cites this paper
• Lactate levels and risk of lactic acidosis with metformin in diabetic kidney disease patients.

  2017cites this paper
• Current management of diabetic patients with kidney disease: a renal‑cardio‑endocrine perspective.

  2016cites this paper
• Interactions between kidney disease and diabetes: dangerous liaisons

  2016cites this paper
• Dose-related effects of metformin on acid–base balance and renal function in patients with diabetes who develop acute renal failure: a cross-sectional study

  2016cites this paper
• Comparative Effectiveness Review Disposition of Comments Report

  2016cites this paper
• Some specificities in the management of hyperglycemia in patients with diabetic kidney disease.

  2016cites this paper
• Anti-Hyperglycemic Agents and New-Onset Acute Myocardial Infarction in Diabetic Patients with End-Stage Renal Disease Undergoing Dialysis

  2016cites this paper
• Non Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus and Metabolic Syndrome: the Role of Low-grade Systemic Inflammation Serum Markers ofF Autoimmune Thyroiditis in Euthyroid Women with Polycystic Ovary Syndrome

  2016cites this paper
• Oral antidiabetics use among diabetic type 2 patients with chronic kidney disease. Do nephrologists take account of recommendations?

  2016cites this paper
• Investigation of Risk Factors Affecting Lactate Levels in Japanese Patients Treated with Metformin.

  2016cites this paper
• chorego – stanowisko American Diabetes Association ( ADA ) i European Association for the Study of Diabetes ( EASD )

  2016cites this paper
• Diabetische Nierenerkrankung – Update 2016

  2016cites this paper
• Metformin in advanced chronic kidney disease: are current guidelines overly restrictive?

  2016cites this paper
• Metformin-related lactic acidosis: is it a myth or an underestimated reality?

  2016cites this paper
• Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study

  2016cites this paper
• Hyperpolarized 13C Magnetic Resonance Treatment Response Monitoring: A New Paradigm for Multiorgan Metabolic Assessment of Pharmacological Interventions?

  2016cites this paper
• Metformin and its use in chronic kidney disease, cardiovascular disease and cancer

  2015cites this paper
• Management of Hyperglycemia in Patients with Chronic Kidney Disease and Dialysis

  2015cites this paper
• Oral antihyperglycemic treatment options for type 2 diabetes mellitus.

  2015cites this paper
• Metformin and other antidiabetic agents in renal failure patients.

  2015cites this paper
• Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2015cites this paper
• Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease

  2015cites this paper
• Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.

  2015cites this paper
• Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study.

  2015cites this paper
• Unique glycemic and cardio-renal protective effects of metformin therapy among type-2 diabetic patients: a lesson from a five-year cross-sectional observational study of 1590 patients

  2014cites this paper
• Drug-Related Problems in Patients with Benign Prostatic Hyperplasia: A Cross Sectional Retrospective Study

  2014cites this paper
• My patient's diabetic kidney disease has progressed to stage 4; should I discontinue metformin?

  2014cites this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2014cites this paper
• [Treatment of type 2 diabetes mellitus in patients with chronic kidney disease. Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica].

  2014cites this paper
• Novel Hypoglycaemic Agents: Considerations in Patients with Chronic Kidney Disease

  2014cites this paper
• [Consensus document on treatment of type 2 diabetes in patients with chronic kidney disease].

  2014cites this paper
• Metformin in Chronic Kidney Disease: Time for a Rethink

  2014cites this paper
• Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

  2014cites this paper
• A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure

  2014cites this paper
• Diabetes treatment in patients with renal disease: Is the landscape clear enough?

  2014cites this paper
• Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica

  2014cites this paper
• Fatal metformin overdose: case report and postmortem biochemistry contribution

  2014cites this paper
• Pharmacist review prevents evolving metformin‐associated lactic acidosis

  2014cites this paper
• Risk of Lactic Acidosis or Elevated Lactate Concentrations in Metformin Users With Renal Impairment: A Population-Based Cohort Study

  2014cites this paper
• Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

  2014cites this paper
• Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

  2014cites this paper
• Comment je traite ... par metformine un patient diabetique avec insuffisance renale moderee.

  2013cites this paper
• La Biochimica Forense: Stato dell'Arte, Prospettive Future e Presentazione di un Caso di Responsabilità Professionale Medica.

  2013cites this paper
• Carbohydrate Metabolism in Kidney Disease and Kidney Failure

  2013cites this paper
• Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

  2013cites this paper
• The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis

  2013cites this paper
• Management of Post-Transplant Diabetes

  2013cites this paper
• Age, Renal Dysfunction, Cardiovascular Disease, and Antihyperglycemic Treatment in Type 2 Diabetes Mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study

  2013cites this paper
• Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease.

  2013cites this paper
• Metformin in patients with chronic kidney disease: strengths and weaknesses.

  2013cites this paper
• Unleash Metformin

  2013cites this paper
• Population Pharmacokinetics of Metformin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus: Simulation of Doses According to Renal Function

  2013cites this paper
• Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes.

  2013cites this paper
• Metformin use in chronic kidney disease: new evidence to guide dosing.

  2013cites this paper
• Renoprotective effects of metformin

  2013influential citation
• Use of Available Glucose-Lowering Agents in Patients with Different Levels of Renal Impairment

  2013cites this paper
• Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment

  2012influential citation
• Dosage of Antihyperglycemic Drugs in Patients with Renal Insufficiency

  2012cites this paper
• Metformin and heart failure: never say never again

  2012cites this paper
• Utilisation des antidiabetiques oraux en cas d'insuffisance renale.

  2012cites this paper
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes

  2012cites this paper
• Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats

  2012cites this paper
• Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients.

  2012cites this paper
• KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update.

  2012cites this paper
• Metformin therapy in patients with chronic kidney disease

  2012cites this paper
• Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology.

  2012cites this paper
• [Proposal for the modification of metformin use in patients with chronic kidney disease].

  2012cites this paper
• Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats

  2012cites this paper
• Metformin and its clinical use: new insights for an old drug in clinical practice

  2012cites this paper
• Le parcours accidenté de la metformine : de l’ombre à la lumière !

  2012cites this paper
• Javaslat a metformin idült vesebetegségben történő alkalmazásának módosítására

  2012cites this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cites this paper
• Cellular and molecular mechanisms of metformin: an overview.

  2012cites this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cites this paper
• A case of lactic acidosis (LA) after administration of tenofovir and metformin in a diabetic patient with recently diagnosed HIV infection.

  2011cites this paper
• Utilization Of Oral Anti-diabetic Medications: Examining Adherence To Clinical Guidelines

  2011cites this paper
• Vascular Health and Risk Management Dovepress How Are Patients with Type 2 Diabetes and Renal Disease Monitored and Managed? Insights from the Observational Oredia Study

  year unknowncites this paper